JP2008527989A5 - - Google Patents

Download PDF

Info

Publication number
JP2008527989A5
JP2008527989A5 JP2007551754A JP2007551754A JP2008527989A5 JP 2008527989 A5 JP2008527989 A5 JP 2008527989A5 JP 2007551754 A JP2007551754 A JP 2007551754A JP 2007551754 A JP2007551754 A JP 2007551754A JP 2008527989 A5 JP2008527989 A5 JP 2008527989A5
Authority
JP
Japan
Prior art keywords
specific binding
binding member
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007551754A
Other languages
English (en)
Japanese (ja)
Other versions
JP5096167B2 (ja
JP2008527989A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2006/000238 external-priority patent/WO2006077441A1/en
Publication of JP2008527989A publication Critical patent/JP2008527989A/ja
Publication of JP2008527989A5 publication Critical patent/JP2008527989A5/ja
Application granted granted Critical
Publication of JP5096167B2 publication Critical patent/JP5096167B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007551754A 2005-01-24 2006-01-24 Ngfに対する特異的結合メンバー Expired - Fee Related JP5096167B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64558705P 2005-01-24 2005-01-24
US60/645,587 2005-01-24
PCT/GB2006/000238 WO2006077441A1 (en) 2005-01-24 2006-01-24 Specific binding members for ngf

Publications (3)

Publication Number Publication Date
JP2008527989A JP2008527989A (ja) 2008-07-31
JP2008527989A5 true JP2008527989A5 (enExample) 2009-03-05
JP5096167B2 JP5096167B2 (ja) 2012-12-12

Family

ID=36088563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007551754A Expired - Fee Related JP5096167B2 (ja) 2005-01-24 2006-01-24 Ngfに対する特異的結合メンバー

Country Status (17)

Country Link
US (2) US9315571B2 (enExample)
EP (2) EP2298345A3 (enExample)
JP (1) JP5096167B2 (enExample)
KR (1) KR101298383B1 (enExample)
CN (1) CN101107268B (enExample)
AU (1) AU2006207338B2 (enExample)
BR (1) BRPI0606933B8 (enExample)
CA (1) CA2595800C (enExample)
ES (1) ES2435691T3 (enExample)
IL (1) IL183752A (enExample)
MX (1) MX2007008722A (enExample)
NO (1) NO343064B1 (enExample)
NZ (1) NZ556157A (enExample)
PT (1) PT1846451E (enExample)
RU (1) RU2406728C2 (enExample)
WO (1) WO2006077441A1 (enExample)
ZA (1) ZA200705754B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032870A2 (en) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 nsaid를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
UA97086C2 (uk) 2003-07-15 2012-01-10 Емджен, Інк. Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf)
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
KR101637908B1 (ko) 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US7488630B2 (en) 2007-03-06 2009-02-10 International Business Machines Corporation Method for preparing 2-dimensional semiconductor devices for integration in a third dimension
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
PL2187964T3 (pl) * 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
BRPI0821383A2 (pt) * 2007-12-20 2015-06-16 Cytos Biotechnology Ag Conjugados de ngf e usos dos mesmos
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
US8530392B2 (en) * 2009-05-13 2013-09-10 Shionogi & Co., Ltd. Test agent for visceral obesity and use thereof
KR20130031247A (ko) 2010-03-17 2013-03-28 애보트 리서치 비.브이. 항―신경 성장 인자(ngf) 항체 조성물
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9783601B2 (en) * 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
RS56876B1 (sr) 2011-08-11 2018-04-30 Astellas Pharma Inc Novo antitelo protiv humanog ngf
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
CA2938066C (en) * 2014-02-02 2025-05-06 Medimmune Limited CHIMERIC PROTEIN COMPOSED OF NERVE GROWTH FACTOR ANTAGONIST DOMAIN AND TUMOR NECROSIS FACTOR-ANTAGONIST DOMAIN-A
WO2016190263A1 (ja) 2015-05-22 2016-12-01 アステラス製薬株式会社 新規抗ヒトNGF抗体Fabフラグメント
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN111417651B (zh) 2017-12-01 2023-09-29 诺华股份有限公司 多瘤病毒中和抗体
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
JPWO2019221097A1 (ja) 2018-05-15 2021-05-27 アステラス製薬株式会社 抗ヒトngf抗体又はその抗原結合フラグメントを有効成分とする心房細動の抑制用医薬組成物
CN113924315B (zh) * 2019-06-10 2022-06-28 山东博安生物技术股份有限公司 抗β-NGF纳米抗体及其应用
WO2021012176A1 (en) 2019-07-23 2021-01-28 Shanghaitech University Asic1 channel antagonist antibody
CN117186219B (zh) * 2020-04-17 2024-07-12 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN117050175B (zh) * 2020-04-17 2024-07-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
IL301548A (en) 2020-09-28 2023-05-01 Medimmune Ltd Compounds and methods for treating pain
CN121410259B (zh) * 2025-12-30 2026-03-20 北京索莱宝科技有限公司 用于检测人β-NGF含量的双抗夹心ELISA试剂盒
CN121987655A (zh) * 2026-02-12 2026-05-08 贵州省人民医院 k-252a在制备抑制肺纤维化药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2097309A1 (en) * 1990-11-30 1992-05-31 Peter S. Distefano Immunoassay and monoclonal antibodies useful for detecting truncated nerve growth factor receptor
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
WO2001027279A1 (en) * 1999-10-12 2001-04-19 Cambridge Antibody Technology Human anti-adipocyte monoclonal antibodies and their use
CA2393292A1 (en) 1999-12-13 2001-06-21 Cambridge Antibody Technology Limited Brain specific binding members
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
KR20100132559A (ko) * 2001-05-30 2010-12-17 제넨테크, 인크. 다양한 질환의 치료에 유용한 항-엔지에프 항체
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003102136A2 (en) * 2002-05-30 2003-12-11 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
EP1545615A4 (en) 2002-10-04 2006-03-01 Rinat Neuroscience Corp METHODS OF TREATING CARDIAC ARRHYTHMIA AND PREVENTING DEATH OF CARDIAC ARRHYTHMIA USING NGF ANTAGONISTS
WO2004032870A2 (en) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
UA97086C2 (uk) * 2003-07-15 2012-01-10 Емджен, Інк. Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf)

Similar Documents

Publication Publication Date Title
RU2495050C2 (ru) Связующий элемент для рецептора gm-csf
DK2574630T3 (en) ANTIBODIES BINDING IL-4 AND / OR IL-13 AND APPLICATIONS THEREOF
RU2007132020A (ru) Партнеры специфического связывания с ngf
JP2022065063A5 (enExample)
TWI511978B (zh) 結合il-17a及il-17f之抗體分子
JP2009533020A5 (enExample)
JP2014508511A5 (enExample)
JP2021524267A5 (enExample)
JP2012070737A5 (enExample)
JP2021513974A5 (enExample)
JP2021101720A5 (enExample)
RU2013123927A (ru) ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4α)-173
RU2014151788A (ru) Молекула, специфически связывающаяся с rsv
RU2011122720A (ru) Члены связывания против il-1r1
JP2008512995A5 (enExample)
JP2011508592A5 (enExample)
MX2009002554A (es) Proteinas de enlace de interleucina-13.
JP2015518857A5 (enExample)
JP2019518473A5 (enExample)
CN114829398B (zh) 对人il-13具有结合特异性的抗体
EP4518906A1 (en) Human interleukin-4 receptor alpha antibody glucocorticoid conjugates
JP2024523034A5 (enExample)
HK40058161B (en) Antibodies that bind il-4 and/or il-13 and their uses
HK40069079A (en) Antibody with binding specificity for human il-13.
RU2009148270A (ru) Молекулы антител человека к il-13